2025-522707-26-00RecruitingPhase 1
A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 Oct 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 2 Jun 2026
- Start date
- 30 Sept 2026
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Metastatic breast cancer
- EU CT number
- 2025-522707-26-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 40
- 8 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (8)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Goethe University Frankfurt | Frankfurt Am Main | Germany | Not yet recruiting |
| Universitaetsklinikum Ulm AoR | Ulm | Germany | Not yet recruiting |
| Hospital Universitario Ramón y Cajal | Madrid | Spain | Not yet recruiting |
| Hospital Clinico Universitario de Valencia | Valencia | Spain | Not yet recruiting |
| Institut Paoli-Calmettes | Marseille | France | Recruiting |
| Oncopole Claudius Regaud | Toulouse Cedex 9 | France | Recruiting |
| Azienda Ospedaliero-Universitaria delle Marche | Ancona | Italy | Not yet recruiting |
| Leids Universitair Medisch Centrum (LUMC) | Leiden | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.